On November 2, 2022 Aptamer Science that ‘CD25-ApDC immune anticancer agent’, an aptamer-based immune cell targeting anticancer drug delivery technology, was selected for the new drug base expansion research project of the National New Drug Development Project (Press release, Aptamer Sciences, NOV 2, 2022, View Source;idx=231 [SID1234641616]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The National New Drug Development Project is a pan-ministerial national R&D project that supports all stages of new drug development to strengthen the global competitiveness of the domestic pharmaceutical and bio industry and secure pharmaceutical sovereignty.
Aptamer Science plans to secure a foundation for expanding aptamer-based drug delivery technology (ApDC) to the area of immunotherapy and anti-cancer drugs by receiving research funding through this project selection and to pursue research in earnest.
‘CD25-ApDC immune anti-cancer drug’ is a treatment that combines a drug with an aptamer that inhibits signal transduction through specific binding to CD25, a biomarker of regulatory T cells that function to suppress immunity in tumor tissue.
The concept is to eliminate tumors by increasing immune activity around the tumor by selectively suppressing the function of Treg cells and relatively inducing the activation of cytotoxic T cells and antigen-labeling cells.
Daegyeon Lee, Director of the New Drug Research Institute, said, "Cancer treatment through controlling the immune environment of tumor tissue is becoming a major strategy that is leading the paradigm shift in overall anticancer drug development.
"As the aptamer-based immunotherapy technology was selected for the national new drug development project, it served as an opportunity to confirm the potential and development competitiveness of the aptamer-drug complex technology that Aptamer Science is focusing on."
"Through this, we have laid the foundation to confirm non-clinical development materials early and promote non-clinical development in earnest," he said.
Aptamer Science attracted 16.5 billion won in investment on October 4 for the purpose of promoting full-scale clinical trials of ‘AST-201 targeted anti-cancer drug’ and developing follow-up pipelines such as new immuno-anticancer drugs and brain disease treatments.
We also plan to promote early technology transfer at the non-clinical stage.
Go to article: Aptamer Science, ‘ApDC immune anti-cancer drug’ selected for national new drug development project